Department of Nursing, China-Japan Union Hospital of Jilin University, Changchun, China.
Department of Gynecology, China-Japan Union Hospital of Jilin University, Changchun, China.
Dis Markers. 2022 Mar 25;2022:6309188. doi: 10.1155/2022/6309188. eCollection 2022.
Diabetes, a common endocrine and metabolic disease in clinical practice, generally manifests a certain defect in insulin secretion due to several factors, thereafter leading to a metabolic disorder such as hyperglycemia. This study was conducted to explore the clinical effects of repaglinide combined with exercise rehabilitation on improving the blood glucose of patients with diabetes.
In this retrospective study, 100 patients with diabetes treated in our hospital from January 2018 to January 2020 were assessed for eligibility and recruited. They were assigned at a ratio of 1 : 1 to receive either repaglinide (control group) or repaglinide plus exercise rehabilitation (experimental group). Outcome measures include fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, time to normal blood glucose, blood glucose fluctuation, insulin dosage, adverse reactions, and blood glucose adequate rate.
All eligible patients showed similar pretreatment fasting blood glucose, glycosylated hemoglobin, and 2 h postprandial blood glucose ( > 0.05). After treatment, repaglinide plus exercise rehabilitation resulted in lower levels of fasting blood glucose, glycosylated hemoglobin, and 2 h postprandial blood glucose versus repaglinide alone ( < 0.05). Repaglinide plus exercise rehabilitation was associated with a significantly shorter time to normal blood glucose and a milder fluctuation versus repaglinide ( < 0.05). The incidence of adverse reactions and blood glucose adequate rate was 6% and 94% in the experimental group and 50% and 52% in the control group, respectively ( < 0.05).
Repaglinide plus exercise rehabilitation results in effective blood glucose control and reduced incidence of adverse reactions and yields a promising efficacy, so it is worthy of clinical promotion and application.
糖尿病是临床实践中一种常见的内分泌和代谢疾病,一般由于多种因素导致胰岛素分泌出现一定缺陷,进而导致高血糖等代谢紊乱。本研究旨在探讨瑞格列奈联合运动康复对改善糖尿病患者血糖的临床效果。
本回顾性研究纳入了 2018 年 1 月至 2020 年 1 月期间在我院接受治疗的 100 例糖尿病患者,将他们按照 1:1 的比例分配至瑞格列奈组(对照组)或瑞格列奈+运动康复组(实验组)。观察指标包括空腹血糖、餐后 2 小时血糖、糖化血红蛋白、血糖达标时间、血糖波动情况、胰岛素用量、不良反应和血糖达标率。
所有符合条件的患者在治疗前的空腹血糖、糖化血红蛋白和餐后 2 小时血糖均相似(>0.05)。与瑞格列奈单药治疗相比,瑞格列奈联合运动康复治疗后空腹血糖、糖化血红蛋白和餐后 2 小时血糖均更低(<0.05)。与瑞格列奈单药治疗相比,瑞格列奈联合运动康复治疗的血糖达标时间更短,血糖波动更轻(<0.05)。实验组不良反应发生率和血糖达标率分别为 6%和 94%,对照组分别为 50%和 52%,差异均有统计学意义(<0.05)。
瑞格列奈联合运动康复可有效控制血糖,降低不良反应发生率,疗效显著,值得临床推广应用。